PuSH - Publikationsserver des Helmholtz Zentrums München: Costs of adverse drug events in German hospitals

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Rottenkolber, D. ; Hasford, J.* ; Stausberg, J.*

Costs of adverse drug events in German hospitals - a microcosting study.

Value Health 15, 868-875 (2012)

Verlagsversion Volltext

DOI

PMC

	Closed

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

Objective: In Germany, only limited data are available to quantify the attributable resource utilization associated with adverse drug events (ADEs). The aim of this study was twofold: first, to calculate the direct treatment costs associated with ADEs leading to hospitalization and, second, to derive the excess costs and extra hospital days attributable to ADEs of inpatient treatments in selected German hospitals. Methods: This was a retrospective and medical record-based study performed from the hospitals' perspective based on administrative accounting data from three hospitals (49,462 patients) in Germany. Total treatment costs ("analysis 1") and excess costs (i.e., incremental resource utilization) between patients suffering from an ADE and those without ADEs were calculated by means of a propensity score-based matching algorithm ("analysis 2"). Results: Mean treatment costs ("analysis 1") of ADEs leading to hospitalization (n = 564) were (sic)1,978 +/- 2,036 (range (sic)191-18,147; median (sic)1,446; (sic)843-2,480 [Q1-Q3]). In analysis 2, the mean costs of inpatients suffering from an ADE (n = 1,891) as a concomitant disease or complication ((sic)5,113 +/- 10,059; range (sic)179-246,288; median (sic)2,701; (sic)1,636-5,111 [Q1-Q3]) were significantly higher ((sic)970; P < 0.0001) than those of non-ADE inpatients ((sic)4,143 +/- 6,968; range (sic)154-148,479; median (sic)2,387; (sic)1,432-4,701 [Q1-Q3]). Mean inpatient length of stay of ADE patients (12.7 +/- 17.2 days) and non-ADE patients (9.8 +/- 11.6 days) differed by 2.9 days (P < 0.0001). A nationwide extrapolation resulted in annual total treatment costs of (sic)1.058 billion. Conclusions: This is one of the first administrative data-based analyses calculating the economic consequences of ADEs in Germany. Further efforts are necessary to improve pharmacotherapy and relieve health care payers of preventable treatment costs.

Impact Factor

Scopus SNIP

Web of Science
Times Cited

Scopus
Cited By

Altmetric

2.191

1.169